TY - JOUR
T1 - Effects of cardioselective KATP channel antagonism on basal, stimulated, and ischaemic myocardial function in in vivo failing canine heart
AU - Saavedra, Walter F.
AU - Paolocci, Nazareno
AU - Kass, David A.
PY - 2002
Y1 - 2002
N2 - 1. Inhibition of cardiomyocyte-specific ATP-sensitive potassium (KATP) channels prolongs the action potential during intense ischaemia with attendant antiarrhythmic effects. However, this is accompanied by contractile depression in some models. These changes may be particularly troublesome in dilated cardiomyopathic hearts that display basal systolic dysfunction, limited energy reserve, and prolonged repolarization favouring arrhythmia. Mechanical effects of selective myocyte KATP channel blockade on basal, β-adrenergic stimulated, and ischemic responses were therefore tested in dogs with cardiac failure induced by tachypacing. 2. Cardiovascular function was assessed by pressure - dimension relationships in 10 conscious, chronically instrumented dogs (sonomicrometry/micromanometry), with or without cardiac failure. Cardiomyocyte KATP channels were inhibited by HMR 1098, and data obtained under basal conditions, during epinephrine infusion to raise metabolic demand, during regional ischaemia, and with combined ischaemia + epinephrine. 3. HMR 1098 had no effect on baseline cardiac function nor did it induce arrhythmia in normal or failing hearts. Epinephrine raised cardiac work 65% and oxygen consumption 55%, yet HMR 1098 had no functional effect in either heart condition. Regional ischaemia with or without epinephrine co-stimulation depressed regional and global function, yet both were also unaffected by HMR 1098. There was minimal arrhythmia without HMR 1098, and drug infusion did not alter this. 4. Thus, myocyte-KATP channels play a negligible role modulating intact in vivo cardiac contraction or arrhythmia in normal and failing heart with and without increased metabolic demand and/or regional ischaemia. This supports the feasibility of administering such agents to depressed hearts, despite underlying contractile and electrophysiologic abnormalities.
AB - 1. Inhibition of cardiomyocyte-specific ATP-sensitive potassium (KATP) channels prolongs the action potential during intense ischaemia with attendant antiarrhythmic effects. However, this is accompanied by contractile depression in some models. These changes may be particularly troublesome in dilated cardiomyopathic hearts that display basal systolic dysfunction, limited energy reserve, and prolonged repolarization favouring arrhythmia. Mechanical effects of selective myocyte KATP channel blockade on basal, β-adrenergic stimulated, and ischemic responses were therefore tested in dogs with cardiac failure induced by tachypacing. 2. Cardiovascular function was assessed by pressure - dimension relationships in 10 conscious, chronically instrumented dogs (sonomicrometry/micromanometry), with or without cardiac failure. Cardiomyocyte KATP channels were inhibited by HMR 1098, and data obtained under basal conditions, during epinephrine infusion to raise metabolic demand, during regional ischaemia, and with combined ischaemia + epinephrine. 3. HMR 1098 had no effect on baseline cardiac function nor did it induce arrhythmia in normal or failing hearts. Epinephrine raised cardiac work 65% and oxygen consumption 55%, yet HMR 1098 had no functional effect in either heart condition. Regional ischaemia with or without epinephrine co-stimulation depressed regional and global function, yet both were also unaffected by HMR 1098. There was minimal arrhythmia without HMR 1098, and drug infusion did not alter this. 4. Thus, myocyte-KATP channels play a negligible role modulating intact in vivo cardiac contraction or arrhythmia in normal and failing heart with and without increased metabolic demand and/or regional ischaemia. This supports the feasibility of administering such agents to depressed hearts, despite underlying contractile and electrophysiologic abnormalities.
KW - Contractility
KW - HMR 1098
KW - Heart failure
KW - Ischaemia
KW - Ventricular function
UR - http://www.scopus.com/inward/record.url?scp=0036008605&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0036008605&partnerID=8YFLogxK
U2 - 10.1038/sj.bjp.0704510
DO - 10.1038/sj.bjp.0704510
M3 - Article
C2 - 11834613
AN - SCOPUS:0036008605
SN - 0007-1188
VL - 135
SP - 657
EP - 662
JO - British Journal of Pharmacology
JF - British Journal of Pharmacology
IS - 3
ER -